Earnings release
Page 1
RNS Number : 2441ODiaceutics PLC29 July 2026 Diaceutics PLC H1 2026 Trading Update Strong ARR growth of 75% drives H2 2026 revenue and profit visibility Revenue grows 22% on a constant currency basis to £17.5 million Annual Recurring Revenue ('ARR') up 75% to £28.8 million Order book of £43.7 million with £15.7 million contracted for H2 2026 delivery Gross margin expected to be 87% and Adjusted EBITDA* expected to be £1.1 million Continued growth in number of customer therapeutic brands to 99 as the Company expands into the Precision for Allmarket opportunity Strong balance sheet with no debt and cash of £8.1 million - fully funded to deliver its growth strategy New York, Belfast and London, 29 July 2026 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today provides a trading update for the half year to 30 June 2026 ('H1 2026'), highlighting strong revenue growth, continued addressable market capture and record forward revenue visibility. Ryan Keeling, Diaceutics' Chief Executive Officer, commented: "I am more confident than ever in Diaceutics and the long-term value we can create for shareholders. H1 revenue grew 22% at constant currency to £17.5 million, alongside a material improvement in the quality and visibility of that growth. ARR reached £28.8 million, increasing 75% period-on-period and 45% since December 2025. NRR increased to 146%, while gross churn fell from 19% to just 9%. Customers are staying longer, expanding their relationships and committing through recurring, multi-year contracts, creating a more predictable and durable business with high revenue visibility. We are demonstrating good operating leverage. Revenue is growing faster than the underlying cost base, gross margin increased to 87%, and we expect to report H1 Adjusted EBITDA of £1.1 million. Precision for All is expanding our addressable market, while PMx is creating deeper enterprise relationships and longer-duration recurring revenue. Our proprietary diagnostic data, technology and application of AI provide a differentiated platform from which to capture this opportunity. We enter H2 with record forward visibility. Our £43.7 million order book includes £15.7 million of revenue contracted for H2, which including weighted pipeline, gives 91% visibility on achieving FY 2026 median analyst consensus revenue estimates. We are growing revenues, increasing recurring revenue, retaining and expanding customers, and building our order book to record levels. That combination gives me strong confidence in delivery for FY 2026 and in our continued ability to create significant long-term shareholder value." Trading Update to 30 June 2026 Revenue for H1 2026 is £17.5 million (H1 2025: £14.6 million), representing growth of 20% in the period and equating to a 3-year CAGR of 21%. At constant currency, revenue growth was 22% in the period. The visibility and sustainability of revenues continued to improve during H1 2026 as the business expands its share of the Precision for All market opportunity through fostering its enterprise-wide customer relationships with global pharma and biotech. Annual Recurring Revenue ('ARR') increased 75% to £28.8 million ($38.2 million) as at 30 June 2026 (£16.4 million ($22.6 million) at 30 June 2025), with constant currency ARR growth of 69%. Underpinning this ARR growth was Net Revenue Retention ('NRR') of 146%, and gross ARR churn of 9% (30 June 2025: NRR of 118% and gross churn of 19%). Recurring revenue represented 61% of total revenues over a Trailing Twelve Month ('TTM') period (58% for TTM ended 30 June 2025).
Page 2
Diaceutics continues to work with 18 of the top 20 global pharma companies, and over a TTM period has supported a total of 54 customers across 99 therapeutic brands (TTM ended 31 December 2025: 53 customers and 95 therapeutic brands) as it continues to grow its core Precision Medicine market and expand into the broader Precision for All market. Diaceutics has also continued to grow and mature its PMx offerings with its existing two PMx customers and has seen the ARR from these customers increase to £4.3 million (30 June 2025: £1.4 million). The contracted order book continued to expand and was £43.7 million at 30 June 2026 (£31.7 million at 30 June 2025), growth of 38%. The order book that is expected to be recognised as revenue in H2 2026 was £15.7 million (H2 2025: £9.0 million) and, including weighted pipeline, gives 91% visibility on achieving FY 2026 median analyst consensus revenue estimates** (like for like H1 2025: 79% visibility on FY 2025 reported revenue). Delivering on median consensus revenue estimates would see a 38:62 H1:H2 split of 2026 revenue, similar to and supportive of prior year seasonality (FY 2025: 38:62). Adjusted EBITDA* is expected to be £1.1 million, compared with £0.1 million in H1 2025, while gross margin increased and is expected to be 87% (H1 2025: 83%). This demonstrates emerging operating leverage while the Group continues to invest selectively in AI enablement and sales and marketing capability to drive future growth. Cash at 30 June 2026 increased to £8.1 million, compared with £7.3 million at 31 December 2025, with no debt, and is fully funded to deliver its growth strategy. Diaceutics has seen continued improved cash collection from customers in H1 2026, with no bad debts. The Company continues to enhance its systems and processes to optimise working capital and ultimately enhance free cash flow metrics. The Company has an uncommitted and undrawn facility of £2.0 million, providing additional working capital flexibility if required. Outlook · Entering H2 with strong commercial momentum, increasing market opportunity, improved customer retention and enhanced revenue visibility · Global pharma and biotech customers continue to embrace Precision for All to improve patient access, capture lost revenue and optimize their commercial outcomes · AI is being embedded across the DXRX platform and operating model to enhance customer insights, improve productivity and strengthen the scalability and defensibility of Diaceutics' proprietary data assets · Management's priorities remain disciplined organic growth, recurring revenue expansion, cash conversion and cost control · The success of the Company's strategy and strength of its recurring revenues, order book and pipeline provide the Board confidence that the Company targets for 2026 are on track The Group expects to announce its interim results in late September 2026. All numbers stated are unaudited. *Adjusted EBITDA is earnings before interest, tax, depreciation, amortisation and exceptional items. ** Median analyst consensus estimates for FY 2026 revenue are £46.7 million. Enquiries: Diaceutics PLC Ryan Keeling, Chief Executive Officer Nick Roberts, Chief Financial Officer Tel: +44 (0)28 9040 6500 investorrelations@diaceutics.com Canaccord Genuity Limited (Nomad & Broker) Tel: +44 (0)20 7523 8000 Simon Bridges, Andrew Potts, Harry Rees About Diaceutics At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®. Prior to publication the information communicated in this announcement was deemed by the Company to constitute inside information for the purposes of article 7 of the Market Abuse Regulations (EU) No 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations No 2019/310 ('MAR'). With the publication of this announcement, this information is now considered to be in the public domain. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer.
Page 3
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authorityto act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this informationmay apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the informationcontained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. Forfurther information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END